Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Clin Cancer Res. 2020 Sep 28;27(2):566–574. doi: 10.1158/1078-0432.CCR-20-2371

Figure 1.

Figure 1.

A. Lollipop plot depicting mutations in CDK12 in this prostate cancer cohort with biallelic alterations (n=31); missense mutations are depicted in green, frameshift and non-sense mutations in black.

B. OncoPrint figure representing CDK12 mutations for the bi-allelic tumors in hormone sensitive prostate cancer (HSPC) and metastatic castration-resistant (mCRPC) samples (top figures).

Middle panel shows concomitant alterations in other DNA repair genes and other relevant pathways in prostate cancer, detected on targeted and exome sequencing in diagnostic and/or mCRPC samples. Bottom panel depicts the available immunohistochemistry (IHC) data for PTEN and ATM on the samples sequenced. PTEN and ATM data were respectively available for 16 and 17 samples of the 31 CDK12 biallelic cases.

Grey boxes indicate sample with no available PTEN or ATM results by IHC,